Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating immune complexes in patients with bone tumours.

A S Eiras1, R A Robins, R W Baldwin

  • 1Cancer Research Campaign Laboratories, University of Nottingham, Nottingham NG7 2RD, England.

International Journal of Cancer
|June 15, 1980
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.

Acta neurologica Scandinavica·2016
Same author

Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.

Acta physiologica (Oxford, England)·2015
Same author

T-cell subsets in tumour rejection responses.

Immunology today·2014
Same author

Th17/Th1 phenotype in demyelinating disease.

Cytokine·2010
Same author

Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

Acta neurologica Scandinavica·2008
Same author

Kinetics of immune cell migration at the human ocular surface.

The British journal of ophthalmology·2008
Same journal

Geographical Pattern of Testicular Cancer Points to Maternal Exposures Behind Increasing Incidence.

International journal of cancer·2026
Same journal

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.

International journal of cancer·2026
Same journal

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.

International journal of cancer·2026
Same journal

Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.

International journal of cancer·2026
Same journal

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy.

International journal of cancer·2026
Same journal

Leveraging Minimal Variables for Maximal Screening Yield: A Global Equity Perspective on Colorectal Cancer Risk Stratification.

International journal of cancer·2026
See all related articles

Immune complexes, detected by the 125I-Clq binding assay, are elevated in patients with bone tumors like osteogenic sarcoma and malignant giant-cell tumors, suggesting potential diagnostic value.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Immune complexes are implicated in various pathological conditions.
  • Their role in bone tumors requires further investigation.

Purpose of the Study:

  • To investigate the presence of immune complexes in patients with bone tumors.
  • To evaluate the diagnostic utility of the 125I-Clq binding assay for bone tumors.

Main Methods:

  • Sera from patients with osteogenic sarcoma, malignant giant-cell tumor, benign bone tumors, and healthy donors were analyzed.
  • The 125I-Clq binding assay was employed to detect immune complexes.

Main Results:

  • Elevated Clq binding activity was observed in 67.7% of osteogenic sarcoma patients and 75% of malignant giant-cell tumor patients.

Related Experiment Videos

  • No elevated activity was found in benign bone tumor patients (0%) or normal donors (5%).
  • Post-operative samples showed decreased Clq binding in some giant-cell tumor patients.

    • Conclusions:

    • The 125I-Clq binding assay can detect immune complexes in patients with malignant bone tumors.
    • This assay shows potential as a monitoring tool for patients with bone tumors.